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We evaluated the diagnostic accuracy of the urine lipoarabinomannan (LAM) antigen detec-
tion assay (Clearview TB-ELISA) to screen for tuberculosis in a South African correctional
facility.
Methods
Between September 2009 and October 2010, male offenders were screened for tuberculo-
sis (symptoms, chest radiograph, two spot sputum specimens for microscopy and culture),
and urine tested for LAM. Sensitivity, specificity and predictive values of LAM were calculat-
ed using definite and probable tuberculosis combined as our gold standard.
Findings
33/871 (3.8%) participants (26% HIV-positive) had tuberculosis. Amongst HIV-positive vs.
HIV-negative offenders the sensitivity and specificity of LAM was 7.1% vs. 0% and 98.5%
vs. 99.8% respectively.
Conclusion
Urine LAM ELISA has inadequate sensitivity for TB screening in this population.
Introduction
Incarcerated populations worldwide suffer disproportionately high risk of both tuberculosis
(TB) [1] and HIV infection,[2] a potent risk factor for TB. In response to the burden of
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tuberculosis and HIV in its correctional facilities, South Africa recently published national
guidelines recommending symptom-based TB screening for all inmates bi-annually, on entry,
exit or transfer, and self-presentation, with GeneXpert MTB/RIF as the initial diagnostic test
for those requiring further evaluation.[3]
Tests for lipoarabinomannan (LAM), a cell wall lipopolysaccharide specific to mycobacteria
that is detectable in urine, are a potentially attractive screening tool for correctional facilities,
given the potential for rapid TB diagnosis, the low infection risk posed and ease of sample col-
lection. Evaluations of a commercially available urine LAM ELISA (Clearview TB-ELISA;
Alere, USA) have demonstrated sensitivity of 21–38% for culture-proven TB in HIV-positive
individuals, [4, 5] which increases to 67% in those with CD4 cell counts<50 cells/μl.[5]
The aim of our study was, within the context of a TB prevalence survey in one of South
Africa's largest correctional facilities,[6] to evaluate the diagnostic accuracy of the Clearview
TB-ELISA for urine LAM to screen offenders for TB.
Methods
Ethics statement
The study was approved by the Research Ethics Committees of the Department of Correctional
Services, South Africa, the University of KwaZulu-Natal, South Africa, and the London School
of Hygiene & Tropical Medicine, United Kingdom; and the Centre for Disease Control Institu-
tional Review Board. The study was also approved by the Office for Human Research Protec-
tions, USA. All participants gave written informed consent, or witnessed verbal consent if
unable to write. Consent and participation in the study was voluntary. Participants were able to
refuse to take part, with no consequences to their healthcare or any other services as a result
of this.
Study population and procedures
The study site and procedures have been described previously.[6] We enrolled a random sam-
ple of offenders who had been incarcerated for at least six months ("currently incarcerated")
and a consecutive sample of "newly sentenced" offenders. Individuals with an expected stay of
less than 3 months in the study facility were excluded to ensure follow-up of medical records.
All participants underwent a standardised symptom-screening questionnaire (any symptom
compatible with tuberculosis, including cough, fever, night sweats, or unintentional weight
loss), chest radiography (assessed by two readers using a standardised tool), and provided two
spot sputum specimens for smear and mycobacterial culture. Urine for anonymised HIV test-
ing was collected from those consenting, and an additional urine sample stored at -20°C on the
day of collection for subsequent LAMmeasurement. Correctional facility medical records were
reviewed 3 months post-enrolment to ascertain any additional TB diagnoses made within three
months of enrolment and thus strengthen the gold standard. HIV counselling and testing was
provided for offenders who wished to know their HIV status.
Sputum specimens underwent fluorochrome microscopy and liquid culture using the My-
cobacterial Growth Indicator Tube (BACTEC-MGIT 960). Positive mycobacterial cultures
were speciated using the GenoType Mycobacterium CM kit (Hain Lifescience, Nehren, Ger-
many). Anonymised urine samples were tested for HIV antibodies using the MAXIM HIV-1
urine EIA (Maxim Biomedical Inc, MD, USA). Urine LAM testing was performed on stored
samples in batches using Clearview TB ELISA (Inverness Medical Innovations, Scarborough,
ME, USA).
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Case definition
TB was classified as definite if one sputum culture was positive forM. tuberculosis and there
were either compatible clinical or radiological features, or additional microbiological confirma-
tion (any grade of smear or further positive culture); probable if either only one culture was
positive without compatible clinical or radiological features; or1 sputum smear-positive
(grade 1+) and culture-negative; possible if classical radiological features on consensus (pleu-
ral effusion, cavitation, or upper lobe changes); or1 scanty positive smear and culture-nega-
tive, without compatible clinical or radiological features.
Statistical analysis
We calculated sensitivity, specificity and predictive values of the LAM assay, using definite and
probable tuberculosis combined as our gold standard. We excluded possible TB cases, those al-
ready on TB treatment at enrolment, and those without a full set of TB screening investigations
from this analysis.
Results
Fig 1 summarises study inclusions, exclusions, case definitions, and urine LAM test results. Be-
tween September 2009 and October 2010, a total of 981 offenders were enrolled to the study.
Amongst 871 evaluable participants, 871 (100%) were male, 812 (93%) were Black African, the
median age was 32 (interquartile range [IQR] 27–38) years, 275 (32%) shared a cell with>50
Fig 1. Participant flow chart. LAM = lipoarabinomannan; TB = tuberculosis; S +ve = sputum smear-positive
for acid-fast bacilli; S –ve = sputum smear-negative for acid-fast bacilli; C +ve = sputum culture-positive forM.
tuberculosis; C –ve = sputum culture-negative forM. tuberculosis; CXR +ve = classical radiographic features
of TB.
doi:10.1371/journal.pone.0127956.g001
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offenders, and 110 (12.6%) reported at least one previous course of TB treatment. Median in-
carceration time in “currently incarcerated” offenders was 74 (IQR 43–103) months, and medi-
an detention in remand for new entrants was 14 (IQR 6–27) months. 222/871 (25.5%)
offenders had a positive urine HIV test result.
33/871 (3.8%) participants fulfilled our case definition for definite and probable TB com-
bined; five were smear-positive and 12 had any symptom compatible with TB. TB prevalence
was greater amongst HIV-positive compared with HIV-negative offenders, 6.6% (14/212) vs.
3.0% (19/632), (P = 0.02).
5/871 (0.6%) participants had a positive LAM test result, of whom one was HIV-positive
and sputum culture-positive forM. tuberculosis. Table 1 summarises the performance of the
urine LAM test in our study population. Amongst HIV-positive offenders the sensitivity and
specificity of the LAM assay were 7.1% (95% confidence interval [CI] 0.2%, 33.9%) and 98.5%
(95% CI 95.6%, 99.7%) respectively. Amongst HIV-negative offenders the sensitivity and speci-
ficity of the LAM assay were 0% and 99.8% (95% CI 99.1%,>99.9%) respectively. The only TB
case correctly identified by the urine LAM test was in an HIV-positive individual who was
smear-negative, culture-positive, with compatible clinical but no radiological features of TB.
Discussion
Our study has shown that the sensitivity of Clearview TB-ELISA is too low to be useful for the
general screening of offenders in this correctional facility, of whom the majority are HIV-nega-
tive. Sensitivity was greater in those who were HIV-positive, in keeping with findings from a
recent meta-analysis.[7] Indeed Clearview TB-ELISA is licensed as a screening test only in
HIV-positive TB suspects. Evaluations amongst HIV-infected TB suspects have suggested that
lateral flow urine test for LAM (Determine TB-LAM; Alere, USA) may be useful to rule-in TB
in hospitalised patients with advanced immunosuppression with sensitivity and specificity of
66% for culture-proven TB [8]; and that the sensitivity of combination of smear microscopy
with lateral flow LAM (72%) approaches that of Xpert MTB/RIF alone, [9] the latter study sug-
gesting that these tests identified different groups of patients with TB. One limitation of our
study is the lack of CD4 cell counts in those offenders confirmed to be HIV positive, and a pos-
sible explanation for the very low sensitivity (7%) amongst HIV-positive offenders, compared
with other published data may be higher median CD4 cell count in this “healthier” population.
Despite the high prevalence of both HIV and TB among offenders, the low sensitivity of the
urine LAM ELISA precludes recommendation of this test as a screening test for TB in this pop-
ulation. The results of our study reinforce the knowledge that the LAM assay, as reported previ-
ously in the literature, is not useful in populations with unknown HIV status and CD4 cell
counts. [4, 7]
Table 1. Performance of urine LAM test overall and stratified by HIV status compared with gold standard of bacteriologically-confirmed TB.
Group Prevalence of TB Prevalence of positive LAM Sensitivity Specificity PPV NPV
% (n) % (n) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Overall (n = 844) 3.9 (33) 0.6 (5) 3.0 (0.1–15.8) 99.5 (98.7–99.9) 20.0 (0.5–71.6) 96.2 (94.7–97.4)
HIV-positive (n = 212) 6.6 (14) 1.9 (4) 7.1 (0.2–33.9) 98.5 (95.6–99.7) 25.0 (0.6–80.6) 93.8 (89.5–96.6)
HIV-negative (n = 632) 3.0 (19) 0.2 (1) 0 (0–17.6) 99.8 (99.1->99.9) 0 (0–97.5) 97.0 (95.3–98.2)
NPV = negative predictive value; PPV = positive predictive value; CI confidence interval
27 participants with possible TB have been excluded from this analysis
doi:10.1371/journal.pone.0127956.t001
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